北京时间 2026-08-13 06:59:29 · 供应链分析

COHR财报揭示InP激光器产能紧缺，CPO需求提前，收入高增。

中文翻译

我的主要观点是：商用连续波(CW)激光器供应商现在显得极其重要。但 $COHR 财报的 TLDR（太长不看版）是： “鉴于我们在数据中心业务中看到的收发器需求，我认为在可预见的未来，我们都不会对外销售磷化铟(InP)激光器。” - 如果 $AAOI 无法为第一代共封装光学(CPO)部署提供足够产能，且 $COHR 不对外销售，那么那些对外销售 InP 激光器的公司将获得更高的估值。我想这就是为什么 $MTSI 表示大量客户正迫切地向他们寻求 InP CW DFB 激光器（而他们直到 2027 年底才没有有意义的产能上线）。 $AAOI -> 内部自用 $COHR -> 内部自用买家 -> 寻找产能的选择更少。 “我们的积压订单现已延伸至 2027 财年，基本上已完全预订。我们实际上已预订至 2027 日历年末。” [巨大的需求可见性] - Coherent 还提到了跨越至本十年末的长期协议(LTA)。这在一定程度上印证了 $POET CEO 在其年度股东大会上所说的“三大巨头”未来两年已完全售罄。 “我们目前在组装和测试产能方面并不受限。我们真正受限的是磷化铟生产的爬坡。” - 对于那些关注瓶颈的兄弟们来说，组装/测试并不是瓶颈。 “CPO 需求绝对没有推迟。事实上，情况恰恰相反。我们看到了需求增加，客户的要求被提前。” “我们继续预计来自规模化应用的 CPO 收入将从 2027 年日历年下半年开始流入。” - 如果 $LITE 和 $COHR 确认 CPO 规模化收入将在 2027 年下半年到来，这对其他 CPO 参与者来说是一个巨大的利好传导。 - “到 2027 财年末，季度收入超过 30 亿美元” - $COHR 收入飞速增长所以常规数据如下： - 收入 20.46 亿美元（环比 +13.3%，同比 +33.8%），主要收入增长看起来发生在进入 Q4 至 2027 年期间 - 非公认会计准则毛利率：40.2% 下一季度指引为： - 收入：22-24 亿美元 - 非公认会计准则毛利率：39.5-41.5% 基本上： 16.9 亿 -> 18.1 亿 -> 20.5 亿 -> ~23.0 亿 -> 30 亿（2027 财年末） ~39% -> 39.6% -> 40.2% -> ~40.5%（毛利率）对于营业利润率： 18.0% -> 19.5% -> 19.9% -> 20.3% -> 21.8% 与 $LITE 的利润率增长相比，我对盈利能力的印象稍逊一筹，但 $COHR 的收入规模正在快速增长。

英文原文

My main takeaway was that your merchant CW laser suppliers seem to be EXTREMELY IMPORTANT now. But TLDR of $COHR earnings: "given the demand that we see in our DC business with transceivers, I don’t see any time in the near future where we would be selling indium phosphide lasers externally" - Ton more value placed on companies that sell InP lasers externally if $AAOI can't doesn't enough capacity for first gen-CPO deployments, $COHR not selling externally... I guess that's why $MTSI said a ton of customers are approaching them with urgency for InP CW DFB lasers (and they dont even have meaningful capacity coming online until EOY 2027) $AAOI -> Internal $COHR -> Internal Buyers -> fewer places to look for capacity. "Our backlog now extends out, fiscal 2027 is basically completely booked out. We are booked really through the end of calendar 2027" [ Massive massive demand visibility] - Coherent also mentioned LTAs spanning end of decade. So this kinda reinforces what $POET CEO said at their AGM that the "big 3" are fully sold out next 2 years. "we’re not constrained in the assembly and test capacity right now. We’re really just constrained by the ramp of the indium phosphide production" - Just for the bottleneck bros in terms of assembly/test not a bottleneck. "absolutely no push-out of CPO demand. In fact, it has been the opposite. We have seen demand increase and request from customers’ demand getting pulled in" "we continue to expect revenue from CPO for scale-up applications to start to flow in the second half of calendar 2027" - Big read through on other CPO players for scale up if $LITE, $COHR reaffirm revenue from CPO scale up coming h2027. - "quarterly revenue exceeding $3 billion by the end of fiscal 2027" - $COHR revenue go brrr So for regular numbers it's: - $2.046B revenue (+13.3% Q/Q, +33.8% Y/Y), main revenue ramp looks to be happening entering Q4 into 2027 - Non-GAAP gross margins: 40.2% Next quarter guide is: - Revenue: $2.2–$2.4B revenue - Non-GAAP gross margins: 39.5-41.5% Basically: $1.69B -> $1.81B -> $2.05B -> ~$2.30B -> $3.0B (end of FY 2027) ~39% -> 39.6% -> 40.2% -> ~40.5% (gross margins) For operating margins: 18.0% -> 19.5% -> 19.9% -> 20.3% -> 21.8% Little less impressed compared to $LITE margin growth in terms of profitability, but revenue scale for $COHR growing rapidly.

在 X 上查看原推 ↗